Humira (Adalimumab) (Rheumatoid Arthritis) - Forecast and Market Analysis to 2023

Rheumatoid arthritis (RA) is a chronic autoimmune disease which causes inflammation and deformity of the joints. It affects over seven million individuals in the 10MM covered in this report (US, France, Germany, Italy, Spain, UK, Japan, Australia, China, and India) and the prevalence is expected to grow to just over 8.5 million individuals by 2023. The anti-TNFs have been effective in treating the signs and symptoms of RA and inhibiting progression to erosive bone disease. However, the landscape is quickly changing with the introduction of biosimilars, novel biologics, and a class of oral therapies known as JAK inhibitors, all of which will change the market dynamics between 2013 and 2023. With the anti-TNFs as extremely effective therapies for RA, the market is extremely competitive for new entrants and will undergo further pressure as biosimilars are approved and launch

Browse Detail Report With TOC @ http://www.hexareports.com/report/humira-adalimumab-rheumatoid-arthritis-forecast-and-market-analysis-to-2023/details

Humira (adalimumab) is a recombinant, fully-human, IgG1 mAb that binds to TNFa and blocks its interaction with the p55 and p75 cell-surface receptors, which reduces inflammation and prevents tissue destruction. It was the first fully-humanized mAb TNF inhibitor to enter the market for the treatment of RA.

Scope

- Overview of Rheumatoid Arthritis, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.

- Detailed information on Humira (Adalimumab) including product description, safety and efficacy profiles as well as a SWOT analysis.

- Sales forecast for Humira (Adalimumab) for the top 9 countries from 2013 to 2023.

- Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan, Australia and China.

Reasons To Buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return.

- Stay...